Robert L. Brainin - 16 Jul 2025 Form 4 Insider Report for CHAMPIONS ONCOLOGY, INC. (CSBR)

Role
CEO, Director
Signature
/s/ Robert L. Brainin
Issuer symbol
CSBR
Transactions as of
16 Jul 2025
Net transactions value
+$5,460,000
Form type
4
Filing time
30 Jan 2026, 15:55:35 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Brainin Robert Lawrence CEO, Director C/O CHAMPIONS ONCOLOGY, INC, ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK /s/ Robert L. Brainin 30 Jan 2026 0002088015

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CSBR Option to purchase Common Stock Award $1,755,000 +225,000 +303% $7.80 299,163 16 Jul 2025 Common Stock 225,000 $7.80 Direct F1
transaction CSBR Option to purchase Common Stock Award $487,500 +62,500 +21% $7.80 361,663 16 Jul 2025 Common Stock 62,500 $7.80 Direct F2
transaction CSBR Option to purchase Common Stock Award $487,500 +62,500 +17% $7.80 424,163 16 Jul 2025 Common Stock 62,500 $7.80 Direct F3
transaction CSBR Option to purchase Common Stock Award $1,170,000 +150,000 +35% $7.80 574,163 16 Jul 2025 Common Stock 150,000 $7.80 Direct F4
transaction CSBR Option to purchase Common Stock Award $780,000 +100,000 +17% $7.80 674,163 16 Jul 2025 Common Stock 100,000 $7.80 Direct F5
transaction CSBR Option to purchase Common Stock Award $780,000 +100,000 +15% $7.80 774,163 16 Jul 2025 Common Stock 100,000 $7.80 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter.
F2 The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year).
F3 The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).
F4 The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).
F5 The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price.
F6 The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price.